NRGN is the human homolog of the neuron-specific rat RC3/neurogranin gene. This gene encodes a postsynaptic 78-amino acid protein kinase substrate that binds calmodulin in the absence of calcium, and that has been implicated in dendritic spine formation and synaptic plasticity. In the rat brain RC3 is under thyroid hormone control in specific neuronal subsets in both developing and adult animals. To evaluate whether the human gene is also a target of thyroid hormone we have searched for T 3 -responsive elements in NRGN cloned genomic fragments spanning the whole gene. Labeled DNA fragments were incubated with T 3 receptors (T 3 R) and 9-cis-retinoic acid receptors and immunoprecipitated using an anti T 3 R antibody. A receptorbinding site was localized in the first intron, 3000 bp downstream from the origin of transcription. Footprinting analysis revealed the sequence GGATTAAATGAGGTAA, closely related to the consensus T 3 -responsive element of the direct repeat (DR4) type. This sequence binds the T 3 R-9-cis-retinoic acid receptors heterodimers, but not T 3 R monomers or homodimers, and is able to confer regulation by T 3 R and T 3 when fused upstream of the NRGN or thymidine kinase promoters. The data reported in this work suggest that NRGN is a direct target of thyroid hormone in human brain, and that control of expression of this gene could underlay many of the consequences of hypothyroidism on mental states during development as well as in adult subjects. (Endocrinology 140: [335][336][337][338][339][340][341][342][343] 1999) 
binding site was localized in the first intron, 3000 bp downstream from the origin of transcription. Footprinting analysis revealed the sequence GGATTAAATGAGGTAA, closely related to the consensus T 3 -responsive element of the direct repeat (DR4) type. This sequence binds the T 3 R-9-cis-retinoic acid receptors heterodimers, but not T 3 R monomers or homodimers, and is able to confer regulation by T 3 R and T 3 when fused upstream of the NRGN or thymidine kinase promoters. The data reported in this work suggest that NRGN is a direct target of thyroid hormone in human brain, and that control of expression of this gene could underlay many of the consequences of hypothyroidism on mental states during development as well as in adult subjects. (Endocrinology 140: [335] [336] [337] [338] [339] [340] [341] [342] [343] 1999) T HE CALMODULIN-BINDING and protein kinase C substrate, RC3 1 /neurogranin, is a member of a family of proteins expressed in the central nervous system, for which the term calpacitins has been recently proposed (1) (2) (3) . These proteins share many structural features, including a calmodulin-binding domain, and are highly conserved among species. RC3 is predominantly located in the soma, dendrites, and dendritic spines of neuron subsets in the cerebrum, and it is absent from the cerebellum (4 -6) . RC3 regulates the availability of free calmodulin in dendrites, a function modulated by protein kinase C phosphorylation (7, 8) . This is important because the concentration of activated calmodulin in the postsynaptic cell is a function of free calmodulin and Ca 2ϩ ion concentrations, and determines the activation of its distal targets, such as calmodulin kinase II, adenylate cyclase, nitric oxide synthase, calcineurin, cyclic nucleotide phosphodiesterase, etc. (7, 9, 10) . Given these biochemical properties, it has been suggested that RC3 plays a role in dendritic spine formation, long term potentiation, and synaptic plasticity (9 -14) .
RC3 expression is physiologically and developmentally regulated. In rats, thyroid hormone (T 3 ) is an important physiological regulator (15, 16) . Hypothyroid animals show reversibly decreased concentrations of RC3 messenger RNA and protein in discrete areas of the forebrain. Regulation of RC3 expression by thyroid hormone occurs in developing as well as adult animals (17) and correlates to the known morphogenetic actions of thyroid hormone on dendritic spines of cerebral cortex and hippocampal neurons (18, 19) . Regulation by T 3 occurs in other species besides the rat. Thus, the goat RC3 homolog has also shown to be thyroid hormone dependent in vivo (20) . In addition, in mouse-derived hypothalamic GT1-7 cells, thyroid hormone induces an increased RC3 expression, which occurs at the transcriptional level and is independent of new protein synthesis (21) . RC3 regulation by T 3 is therefore presumably mediated through a direct interaction of thyroid hormone receptors with regulatory regions in the RC3 gene. In brain as well as in other tissues, T 3 acts in the cell nucleus after binding to specific receptors. These receptors are members of a large family of transcription factors that includes the receptors for other hydrophobic ligands, such as retinoids, steroid hormones, and other hormones or metabolites. They control important developmental and physiological processes by modulating the expression of genes after binding to specific DNA sequences, known as response elements, that are usually located in the upstream promoter region of the target genes (22) (23) (24) . Most of these nuclear receptors usually bind to DNA as homodimers or heterodimers with the 9-cisretinoic acid receptor (RXR) (25) . In the case of thyroid hormone, the response elements, or T 3 REs, usually consist of a direct repeat of the consensus hexamer sequence, AGGTCA, separated by four nucleotides (DR4), although other configurations are also relatively common (26, 27) .
We have previously reported the identification, cloning, and determination of the structure of the human RC3 homolog gene, which we have named NRGN (28) . The gene spans 12 kb and contains four exons and three introns. Its organization is identical to that of the rat Ng/RC3 gene, and alignment of protein sequences revealed a 97.5% identity. Besides characterization of the gene and chromosomal mapping, few data are available on NRGN expression in humans (29) . We have observed that its expression in the monkey brain follows a pattern similar to that previously described for the rat or goat brain (results to be published). This suggests that NRGN could also be under thyroid hormone regulation in primates. To try to answer this question as well as to disclose the mechanism of regulation by T 3 , we have searched for T 3 REs in the human NRGN gene. Our previous studies failed to disclose any such regulatory elements in the 5Ј-flanking region of the rat or human genes (21, 28, 30) . In the present work we have used an immunoprecipitation technique that allowed the screening of the whole gene. As a result we report on the localization and characterization of a T 3 RE in the first intron of the NRGN gene. The sequence consists of a typical DR4, which binds the RXR-T 3 R heterodimer and is trans-activated in vitro by thyroid hormone when fused to either the homologous promoter or to thymidine kinase promoter. The results provide an explanation for T 3 regulation. In addition, they suggest that, as previously shown in the rat and goat, the NRGN gene is also under thyroid hormone regulation, probably contributing to the effects of this hormone on the development and function of the human brain.
Materials and Methods

Plasmids and oligonucleotides
The following plasmids were used in this study: pBLCAT-2 a chloramphenicol acetyltransferase (CAT) vector, in which the expression of the reporter enzyme is under control of the thymidine kinase promoter; thyroid hormone receptor (T 3 R) expression vector, consisting of the complementary DNA encoding the rat T 3 R␣-1 cloned in pCDM8 (a gift from Dr. P. R. Larsen, Brigham and Women's Hospital, Boston, MA); and retinoid X receptor expression vector, the human RXR␣ complementary DNA, cloned in the plasmid pSG-5 (supplied by Dr. H. Stunnenberg, University of Nijmegen, The Netherlands). The oligonucleotides used in this study were synthesized as two complementary strands with 5Ј-extensions according to the sequence of the NRGN T 3 RE, as shown in this paper, and the T 3 RE present in the long terminal repeat of the Moloney murine leukemia virus (Mo) (31) . The sequences of these nucleotides were as follows (the DR4 half-sites are underlined): NRGN T 3 RE, 5Ј-TCGACTTCCAAAATGGGGATTAAATGAGGTAATATC 3Ј; and Mo T 3 RE, 5Ј-TCGACAGGGTCATTTCAGGTCCTTGC-3Ј.
The nonspecific oligonucleotide (NS) used for the gel retardation experiments consisted of a 43-mer oligonucleotide corresponding to a region of the promoter of rat proteolipid protein with the following sequence: 5Ј-GATCCAAGAGTTTGACTGGCTGATTTCCAGTTTGTG-3Ј.
The mutated oligonucleotides of the NRGN T 3 RE were the following (the nucleotide changes are underlined): M1, 5Ј-TCGACTTCCAAAAT-GGTTATTAAATGAGGTAATATC 3Ј; M2, 5Ј-TCGACTTCCAAAAT-GGGGATTAAATGATTTAATATC 3Ј; and M3, 5Ј-TCGACTTC-CAAAATGGGGATTACTTAAGGTAATATC 3Ј.
The labeled DNA used in the footprinting assay was amplified using the universal primer of the pMosblue vector (Amersham Pharmacia Biotech, Rainham, Essex, UK) (Ϫ40: 5Ј-GTTTTCCCAGTCACGAC-3Ј) and the internal primer of the NRGN fragment (1588: 5Ј-TGACT-TTTCCTGCATTCAC-3Ј).
For trans-activation experiments, a single copy of each of the following oligonucleotides, NRGN T 3 RE, Mo T 3 RE, M1, M2, and M3, was subcloned into the SalI site of pBLCAT-2 vector, which contains the CAT gene under the control of the thymidine kinase promoter. In addition, to evaluate the ability of the NRGN T 3 RE to regulate the activity of the homologous promoter, the T 3 RE was inserted immediately upstream of the NRGN promoter [nucleotides Ϫ513 to ϩ76 (28) ] in the promoterless pBLCAT-3 vector.
Transfection and CAT assays
COS-7 cells were grown and maintained in DMEM supplemented with 10% FBS. The cells were plated to a density of 250,000 cells/6-cm plate the day before transfection. The cells were transfected by the calcium phosphate protocol (32), using 5 g of the appropriate CAT construct, 0.3 g of the expression vector containing the nuclear receptor, and 4 g of the plasmid pCH110 (Amersham Pharmacia Biotech). This plasmid contains the structural gene for ␤-galactosidase under control of the simian virus 40 early promoter and was used as an internal control of transfection efficiency. Sixteen to 18 h after DNA addition the cells were washed with PBS and replenished with medium containing serum depleted of thyroid hormones by treatment with Dowex resin. Where appropriate, T 3 (Sigma Chemical Co., St. Louis, MO) was added to a concentration of 150 nm, and the cells were incubated for 24 h before harvesting for determination of ␤-galactosidase and CAT activities (33) .
Isolation of T 3 R-bound genomic DNA fragments
To isolate DNA fragments able to bind T 3 R we followed an immunoprecipitation method described previously (34) . Plasmid clones spanning the whole NRGN gene (28) were cleaved with different restriction enzymes, and all of the resulting fragments were end labeled with Klenow DNA polymerase and [
32 P]deoxy-CTP. T 3 R␤1 and RXR␣ were obtained by in vitro translation using the TNT kit (TNT Sp6 Coupled Reticulocyte Lysate System, Promega Corp., Madison, WI). The reaction mixture contained 10 5 cpm (4 ϫ 10 7 cpm/g) labeled DNA and 10 -20 fmol of the in vitro translated T 3 R␤ and RXR␣ in 40 l binding buffer [25 mm HEPES (pH 7.9), 100 mm KCl, 1 mm dithiothreitol (DTT), 10% glycerol, and 0,05 mg/ml poly(dI-dC)]. After incubation for 30 min at room temperature, 500 ng anti-T 3 R antibody were added, and incubation was continued for 30 min at room temperature. To recover the immunocomplexes, 20 l 50% protein A-Sepharose, previously equilibrated in binding buffer, were added and mixed during 20 min at room temperature on a rotating wheel.
Protein A-Sepharose was washed three times with 500 l washing buffer [25 mm HEPES (pH 7.9), 100 mm KCl, 1 mm DTT, and 10% glycerol], and the precipitated DNA fragments were eluted with 100 l 1 m NaCl, extracted with phenol-chloroform, and precipitated with 100 l isopropanol and 5 g transfer RNA. The pellet was resuspended in 15 l TE [10 mm Tris-HCl (pH 8) and 1 mm EDTA (pH 8)] and run on a 1% agarose gel, which was then fixed in 10% trichloroacetic acid and dried. The gel was exposed for 12 h at Ϫ70 C.
Footprinting assays
Deoxyribonuclease I (DNase I) footprinting assays were performed with 3 ng (4 ϫ 10 5 cpm) 32 P-labeled, 260-bp BamHI-EcoRV immunoprecipitated fragment, subcloned in pMosblue. The labeled probe was obtained by PCR amplification using the universal primer of the vector, labeled at one end with T4 polynucleotide kinase, plus an unlabeled internal primer of the fragment. The PCR conditions were: 5 min at 94 C; 35 cycles of 30 sec at 94 C, 30 sec at 55 C, and 1 min at 72 C; and 7 min at 72 C. Nuclear extracts from HeLa cells infected with vaccinia virus expression vectors for the T 3 R␣ and RXR␣ (a gift from Dr. H. Stunnenberg) were incubated in 40 l binding buffer [25 mm HEPES (pH 7.9), 100 mm KCl, 1 mm DTT, 10% glycerol, and 0.05 mg/ml poly(dI-dC)]. After 5-min incubation at room temperature, the radioactive probe was added and incubated for a further 30 min. Increasing amounts of DNase I were then added, and incubation was continued for 1 additional min. The reaction was terminated on ice by adding stop buffer (25 mm EDTA and 1% SDS). Samples were extracted with phenol/chloroform and ethanol precipitated. Pellets were resuspended in 6 l water and 5 l formamide loading buffer (80% formamide, 20 mm EDTA, 0.025% bromophenol blue, and 0.025% xylene-cyanol) and boiled for 3 min before loading on a 8% polyacrylamide-7 m urea sequencing gel. Electrophoresis was carried out at room temperature in 1 ϫ Tris-borate buffer (89 mm Tris base, 88 mm boric acid, and 2 mm EDTA). As a control, 6 g BSA, instead of nuclear receptors, were used in parallel reactions.
Electrophoretic mobility shift assays (EMSA)
To study the interaction of T 3 R and RXR proteins with DNA, we used in vitro translated nuclear receptors. Complementary oligonucleotides were annealed, labeled with T4 polynucleotide kinase and [␥-32 P]ATP, and purified with QIAquick Nucleotide Removal Kit (Qiagen, Chatsworth, CA). The translated receptors were incubated in 13 l binding buffer [15% glycerol, 5 mm MgCl 2 , 50 mm KCl, 20 mm HEPES (pH 7.9), 5 mm DTT, and 0.3 mg/ml poly(dI-dC)] at room temperature. After 15 min, labeled probes (4 ϫ 10 4 cpm) were added to the binding mixture, and incubation was continued for 15 min. Competition gel-shift studies were carried out by adding the indicated amounts of the competitor oligonucleotide at the same time as the probe. The protein-DNA complexes formed during binding reactions were separated on 6% polyacrylamide gels in 0.25 ϫ Tris-borate buffer at 250 V. The gels were dried and exposed to films.
Supershift analysis was carried out by the addition of 1 l of an anti-T 3 R antibody to the gel shift reaction after the 30-min incubation. The reaction mixture was incubated on ice for an additional 30 min and then loaded on the gel.
For off-rate experiments, a 200-fold molar excess of unlabeled oligonucleotides was added after the binding reaction. Samples were withdrawn at intervals between 0 -45 min and directly loaded on a running gel. These experiments were performed in the presence of either 1 mm EDTA or 1 mm MgCl 2 in the binding buffer (35) .
Results
Detection of a T 3 R binding site in the first intron of the human neurogranin gene
Previous studies using genomic clones of the rat RC3 and human NRGN genes failed to show the presence of T 3 REs in the corresponding upstream promoter regions (28, 30) . The fact that T 3 induces expression of RC3 at the transcriptional level, both in vivo and in cultured cells (21, 36) , and that the effect on cultured cells was relatively fast and independent of protein synthesis prompted us to analyze other regions of the gene in search of putative T 3 RE sequences. The human gene was used as starting material for these studies for two reasons: firstly for convenience, because we had genomic clones available from a previous study (28) , and secondly for biological relevance, because the presence of a T 3 RE would strongly suggest that NRGN gene is also under T 3 regulation.
We followed an immunoprecipitation technique to isolate genomic fragments able to bind the T 3 receptor protein (34) . NRGN genomic clones were cleaved by a set of restriction enzymes, followed by end labeling of the resulting DNA fragments. The labeled fragments were then used in coimmunoprecipitation assays in an attempt to identify T 3 REs on the basis of their expected interaction with the receptor. For immunoprecipitations, we used a mixture of T 3 R␤ and RXR␣ proteins, previously obtained in vitro using a coupled transcription and translation rabbit reticulocyte lysate system. Control samples contained unprogrammed reticulocyte lysate. The mixture of labeled DNA fragments was incubated with either control or T 3 R/RXR-programmed lysate proteins, and the resulting complexes were immunoprecipitated with a specific anti-T 3 R antibody. Parallel incubations were performed in the presence of an excess of a DR4 T 3 RE, like the one present in the Moloney murine leukemia virus promoter, to determine the absence of nonspecific binding to DNA. Figure 1A shows the structure of the human gene based on the report by Martinez de Arrieta et al. (28) . The gene contains four exons and three introns. Exon 1 encodes the 5Ј-untranslated region and the first five amino acids of the protein sequence; the rest of the NRGN protein is encoded in exon 2. Exons 1 and 2 are interrupted by an intron of about 5 kb long. In this work, we used several DNA fragments of sizes up to 1.5 kb, encompassing the human gene from about 3 kb upstream from the initiation of transcription to 0.5 kb downstream from the end of the fourth exon. All of these genomic fragments were negative in the immunoprecipitation assays, except for a 1.5-kb fragment of the first intron of the gene from approximately nucleotide 3000 -4500 (Fig. 1A) from the origin of transcription. This fragment was cloned in pMosblue and subjected to further restriction digestion and immunoprecipitation analysis to more precisely delineate the T 3 R-interacting region. Figure 1A shows a restriction enzyme map, and Figure 1B shows the result of immunoprecipitation. Digestion with XbaI plus EcoRI produced four fragments: two of 0.1 kb, one of 1.4 kb, and one of 2.8 kb, the latter containing the vector. The labeled fragments were resolved in agar electrophoresis as three bands (Fig. 1B, lane D) . After incubation with T 3 R/RXR plus an anti-T 3 R antibody (lane R), only the 1.4-kb band was precipitated. The specificity of this effect was confirmed by performing a similar coimmunoprecipitation experiment using as unlabeled competitor an excess of the T 3 RE present in the Moloney murine leukemia virus (lane Mo). In addition, the band was not observed if an unprogrammed reticulocyte lysate (lane RL) was used. Digestion with BamHI produced three bands, consisting of the vector plus two bands of 0.9 and 0.6 kb, respectively. After incubation with receptors and the anti-T 3 R antibody, only the 0.6-kb band was significantly immunoprecipitated. Further digestion and immunoprecipitation of smaller fragments (not shown) narrowed the size range of the DNA able to bind T 3 R/RXR to a 260-bp BamHI-EcoRV fragment derived from the 5Ј-portion of the original fragment.
These results strongly suggested the presence of a T 3 RE in the first intron of the human NRGN. Alignment of the sequences of the human and rat introns (37) showed a high degree of similarity in this region of the first intron, and preliminary immunoprecipitation experiments similar to those described above, but using the rat gene, suggested the presence of a T 3 RE in a similar position (not shown). To further delineate the receptor binding sequence, DNase I footprinting analysis were performed. The 260-bp BamHIEcoRV fragment was subcloned in pMosblue, labeled by PCR in the lower strand, and used in the DNase I footprinting assay. Incubation of the fragment with nuclear extracts from HeLa cells expressing T 3 R␣ and RXR␣, plus increasing amounts of DNase I ( Fig. 2A) resulted in a major protected sequence of 20 nucleotides. Control reactions performed in the presence of BSA showed no protected sequence. Analysis of the protected sequence shown in Fig. 2A reveals an imperfect direct repeat of the consensus half-site AGGTCA separated by four nucleotides (GGATTAaatgAGGTAA) .
To analyze whether the sequence identified in the first intron as a putative T 3 RE was functional in vitro, trans-activation assays were performed (Fig. 2B) . For this purpose, either a 140-bp fragment from the NRGN first intron containing the T 3 RE or a single copy of a double stranded oligonucleotide (NRGN T 3 RE, as shown in Materials and Meth- FIG. 2 . A, DNase I footprinting analysis of the immunoprecipitated 260-bp fragment from the first intron of NRGN. Probe fragment was labeled as described in Materials and Methods. The resulting 260-bp fragment, labeled by PCR on the lower strand, was purified with the QIAquick PCR Purification Kit (Qiagen) and then incubated with either vaccinia virus-expressed T 3 R/RXR␣ proteins or 6 g BSA as a control. The reactions were further digested with increasing amounts of DNase I (1, 2, 3, and 6 g/ml), the fragments were separated on an 8% sequencing gel, and the dried gel was autoradiographed for 36 h. Simultaneously a GϩA Maxam-Gilbert reaction was performed (not shown). B, The NRGN oligonucleotide confers T 3 -dependent regulation when inserted upstream of the thymidine kinase or the NRGN promoter. The upper panel shows activation of the thymidine kinase promoter (tk) by T 3 through the Moloney murine leukemia virus T 3 RE (Mo), the NRGN T 3 RE, or a 140-bp genomic fragment containing the T 3 RE NRGN sequence. The lower panel shows activation of the NRGN promoter (0.6-CAT construct, containing nucleotides Ϫ513 to ϩ76 of the NRGN gene) by the Mo or NRGN T 3 REs. COS-7 cells were cotransfected with the promoter constructs shown together with T 3 R and RXR expression plasmids, and CAT activity was assayed 24 h after the addition of T 3 to a concentration of 150 nM or solvent.
ods) was cloned upstream from the thymidine kinase promoter in the pBLCAT-2 vector (140-tk-CAT or NRGNtk-CAT, respectively). COS-7 cells were cotransfected with either of these two constructs together with expression vectors encoding T 3 R and RXR. For comparison, cells were similarly cotransfected with the CAT expression vector containing a single copy of the strong T 3 RE present in the Moloney murine leukemia virus long terminal repeat, a prototypical DR4 (Mo-tk-CAT). CAT activity was measured after incubating the cells in the absence or presence of T 3 . The cells transfected with either NRGN construct responded to the addition of T 3 with an increased CAT activity (Fig. 2B, upper  panel) . In addition, we checked whether the T 3 RE was able to confer regulation in the context of the NRGN promoter. For this purpose, either the Moloney DR4 or the NRGN T 3 RE was inserted upstream of the NRGN promoter in the promoterless pBLCAT-3 vector (Mo-0.6-CAT and NRGN-0.6-CAT, respectively). In both constructs the addition of T 3 increased CAT activity, whereas it did not when the 0.6-CAT construct without a T 3 RE was used as the control (Fig. 2B, lower panel) .
Interaction of the thyroid hormone receptor with the NRGN T 3 RE
A set of experiments was designed to characterize the interaction of T 3 R in vitro with the NRGN T 3 RE by EMSA, using in vitro translated T 3 R␤ and RXR␣, and labeled oligonucleotides. For comparison, we also used the Moloney T 3 RE (Fig. 3A) . When labeled NRGN T 3 RE oligonucleotide was incubated with human T 3 R␤ and RXR␣ (lane 2), a retarded band was observed showing the same mobility shift than the RXR-T 3 R heterodimer obtained with the Mo T 3 RE (lane 1). Neither T 3 R (lanes 6 and 8) nor RXR (lane 9) alone bound the T 3 RE. The specificity of receptor binding was determined by the addition of an excess of unlabeled competitors. The addition of Mo and NRGN oligonucleotides (lanes 3 and 5) completely avoided formation of the retarded band. The complex was not competed, however, when incubated in the presence of a random DNA sequence (lane 4). Further proof of the binding of T 3 R to the NRGN oligonucleotide was obtained in supershift experiments, as shown in Fig. 3B . In these experiments, the same shifted band was produced with T 3 R/RXR plus either Mo (lane 10) or NRGN (lane 12) oligonucleotides. The NRGN band was supershifted by addition of an anti-T 3 R antibody to the incubation mixture (lane 11), whereas the antibody alone was without effect (lane 13). These experiments suggested that the NRGN T 3 RE bound the RXR-T 3 R heterodimer and had no affinity for either T 3 R monomer or homodimer.
To determine the relative binding strength of RXR-T 3 R heterodimer to NRGN T 3 RE compared with that of the Mo T 3 RE, we measured the time course of dissociation of the preformed complex after adding a homologous oligonucleotide as a competitor (Fig. 4) . These experiments were performed in the presence or absence of Mg 2ϩ (35) . In the absence of Mg 2ϩ , the complex formed on the Mo T 3 RE was very stable, with almost no dissociation after 45 min, a period during which about 20% of the NRGN-receptor complex was dissociated. In the presence of Mg 2ϩ , the half-life of the Mo complex was about 5 min, and that of the NRGN complex was 2 min.
Role of each T 3 RE half site for binding the RXR-T 3 R heterodimer
To evaluate the contribution of each NRGN T 3 RE half-site to the binding of the RXR-T 3 R heterodimer, different mutations in each half-site as well as in the spacer sequence were introduced (Fig. 5A) . The oligonucleotides were labeled and incubated with receptors in the presence or absence of the homologous unlabeled oligonucleotide in a molar excess to determine the specificity of the retarded complex (Fig. 5B) . The substitution of two thymidines for two guanines in the first half-site (M1) reduced the ability to bind the receptors. The same mutation in the second half-site (M2) completely suppressed the formation of the retarded band. Exchange of the wild-type spacer sequence for another functional sequence, CTTA (M3) (38) , produced a similar retarded band as with the NRGN oligonucleotide. In Fig. 5C , the labeled NRGN oligonucleotide was incubated with increasing amounts of competing oligonucleotides, such as the wildtype sequence; the mutants M1, M2, and M3; and a nonspecific sequence (NS). Consistent with the results shown in Fig.  5B , when the wild-type sequence and that with the mutated spacer (M3) were used, a small excess of cold oligonucleotide strongly decreased the labeled DNA-protein complex, whereas a nonspecific sequence had no competitor activity. Modification of the first half-site (M1) decreased the competing effect, but did not obliterate it completely. In contrast, when the second half-site was modified (M2), the competing effect of the oligonucleotide was completely lost. These results suggest that the integrity of the second half-site is essential for binding the RXR-T 3 R heterodimer.
Discussion
Control of the RC3 gene might be an important feature of thyroid hormone action in the brain, not only during the critical developmental stages, but also in adult animals (15, 17) . RC3 has been shown to be under thyroid control in rats and goats, but it is not known whether the human RC3 homolog, NRGN, is under similar control in humans. Several genes have been reported to be regulated by thyroid hormone in some species but not in others, such as pituitary GH, which is under control by T 3 in rats but not in humans (39) . Considering the severe consequences of thyroid hormone deprivation on human brain development and function (40 - 
42)
, it is important to identify what genes from those found to be regulated in the rat are also regulated by thyroid hormone in the human. Moreover, the RC3 gene is of great interest because its control by thyroid hormone is reversible, even in adult animals. Therefore, if regulated in humans, it might be responsible for some of the effects of hypothyroidism on mental states, such as impaired ability to learn and memory loss. In this respect, even mild deficiencies of thyroid hormones, such as those present in subclinical hypothyroidism, are often accompanied by impaired memory (43) . As RC3/NRGN is involved in postsynaptic mechanisms leading to various forms of synaptic plasticity, it is tempting to postulate that an impaired control of NRGN expression might underlay some of these symptoms. The presence of a T 3 RE in the first intron of the gene, as shown here, strongly suggests that NRGN is a target of thyroid hormone in the human brain. The T 3 RE was localized using a previously described technique that allowed the isolation of T 3 target genes from genomic libraries (34, 44) . Further characterization of the T 3 RE sequence was carried out by footprinting, EMSA, and trans-activation analysis. The footprinted sequence from NRGN contains an imperfect DR4 sequence (ggGGATTAaatgAGGTAA), with the second halfsite almost identical to the consensus sequence. It binds the RXR-T 3 R heterodimer, but not T 3 R monomers or dimers, as with other DR4 sequences that contain guanosine in the spacer sequence between the half-sites and lack TC or TA motifs upstream of the first half-site (25) . The half-life of the complex is similar to that of the strong T 3 RE present in the Moloney virus terminal repeat, and the protein complex shifted in the EMSA experiments was supershifted with an anti-T 3 R antibody. Mutations of the two half-sites revealed the requirement for the integrity of the second half-site to bind the complex, in agreement with the known polarity of the RXR-T 3 R heterodimer binding to DNA. Current models suggest that T 3 R binds first to the distal half-site, and subsequent binding of RXR increases binding affinity (45, 46) . Interestingly, NRGN T 3 RE is located in the first intron of the gene, and preliminary data from our laboratory suggest that a T 3 R-binding site is located in a similar position in the first intron of the rat RC3 gene, in a conserved region of the intron showing a high degree of similarity to the human gene. Although most of the reported T 3 REs are located in the upstream promoter region of the target genes, T 3 REs in intronic locations have also been described, such as in the rat GH gene, NCAM, and Pcp2 (39, 47, 48) . Among the thyroid hormone-dependent genes in brain only a few of them have been shown to contain T 3 REs. These include myelin basic protein (49) , NCAM (47), tubulin (47), Pcp2 (48) , and PGD2 synthase (50) . NRGN is the second human brain gene, after PGD2 synthase (51) , in which a T 3 RE has been identified.
Previous studies in the rat have shown that the control exerted by thyroid hormone on RC3 expression is region specific (16) . Some neuronal populations were sensitive, whereas others insensitive to the effects produced by either thyroid hormone deprivation or supplementation. The sensitive regions were layer 6 of the cerebral cortex, layers 2-3 of retrosplenial cortex, the lateral caudate, and the granular layer of the hippocampus. The insensitive regions included, among others, the upper layers of cerebral cortex, the pyra- midal layers of the hippocampus, and the amygdala. The fact that RC3 expression is modulated by thyroid hormone in specific regions suggested that the T 3 control was indirect, so that RC3 could be a distal response subsequent to activation of an earlier responsive gene. However, as pointed out above, T 3 induces RC3 expression in cultured cells at the transcriptional level and does not require protein synthesis (21) . The finding of a T 3 RE in NRGN provides further support for a direct interaction of thyroid hormone receptors with regulatory sequences in this gene. Therefore, the reasons for differential T 3 sensitivity remain to be determined. We have previously discarded the idea that this phenomenon is due to differential expression of thyroid hormone receptor isoforms (36) . Other possibilities to be explored are differential expression of T 3 R coregulators or an effect due to chromatin conformation.
